Compare SVM & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SVM | IRON |
|---|---|---|
| Founded | N/A | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.6B |
| IPO Year | 2005 | 2020 |
| Metric | SVM | IRON |
|---|---|---|
| Price | $9.55 | $76.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $10.50 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 4.0M | 813.6K |
| Earning Date | 05-25-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.22% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.87 | N/A |
| Revenue Next Year | $35.34 | $283.52 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.26 | $40.00 |
| 52 Week High | $15.77 | $99.50 |
| Indicator | SVM | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 38.98 | 60.12 |
| Support Level | $8.78 | $70.29 |
| Resistance Level | $13.29 | $82.70 |
| Average True Range (ATR) | 0.55 | 3.35 |
| MACD | -0.08 | 0.53 |
| Stochastic Oscillator | 29.73 | 55.59 |
Silvercorp Metals Inc is engaged in the acquisition, exploration, development, and mining of mineral properties. The Company's producing mines are located in China, and current exploration and development projects are located in China, Ecuador and Kyrgyz Republic. The company operates in single segment. The Company mainly produces and sells silver, lead, zinc, gold and other metals. The company's producing projects are Ying Mining District, GC Mine; construction projects are El Domo; permitting project is BYP Mine; development project includes Condor, Tulkubash/Kyzyltash.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.